Abstract
Clinical trials and real-world studies reported that canagliflozin (CANA) improved HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM). This study examines if previous results hold regionally and within specific patient sub-groups. Adults with T2DM and ≥12 months of clinical activity before the first CANA prescription (index) were identified in electronic medical records (January 1, 2012-February 15, 2017) from a network of hospitals in Florida. Quality measures were described at baseline and 3, 6, 9, and 12 months post-index. Selected thresholds were HbA1c < 7%, BP < 140/90 mmHg, and weight loss ≥5%. Sub-groups included patients ≥65 years old, with African American race, with CANA dose increase, initiating CANA in an endocrinology setting, and initiating CANA in a primary care setting. Overall, 1,259 patients (mean age = 56.7 years; 51.2% female, 70.4% White) were identified. Among patients with a baseline HbA1c ≥ 7%, 16.1% had an HbA1c < 7% 3 months following CANA initiation, and the mean HbA1c decreased from 8.8% to 8.1%. Among patients with a baseline systolic BP ≥140 mmHg or diastolic BP ≥ 90 mmHg, 59.3% attained a systolic BP < 140 mmHg and 77.3% a diastolic BP < 90 mmHg after 3 months....Continue Reading
References
Mar 1, 1991·Diabetes Care·R A DeFronzo, E Ferrannini
Jan 1, 1987·Journal of Chronic Diseases·M E CharlsonC R MacKenzie
Mar 15, 2003·Diabetologia·S E Kahn
Aug 25, 2004·Current Medical Research and Opinion·Andrew J PalmerGiatgen A Spinas
Jan 22, 2005·Science·Christopher J Rhodes
Aug 29, 2006·Diabetes Care·Zachary T BloomgardenSilvio E Inzucchi
Jun 28, 2007·International Journal of Clinical Practice. Supplement·E Standl
Mar 17, 2010·The American Journal of Medicine·Mark Stolar
Nov 15, 2011·Diabetes Research and Clinical Practice·David R WhitingJonathan Shaw
Jan 3, 2013·Diabetes, Obesity & Metabolism·K StenlöfG Meininger
Mar 8, 2013·Diabetes, Obesity & Metabolism·J-F YaleG Meininger
Apr 9, 2013·Diabetes Care·Guntram SchernthanerGary Meininger
Jul 16, 2013·Lancet·William T CefaluGary Meininger
Sep 13, 2013·Diabetologia·F J Lavalle-GonzálezG Meininger
Nov 23, 2013·Parkinsonism & Related Disorders·Roselyne M RijsmanMaartje Louter
Feb 18, 2014·Diabetes, Obesity & Metabolism·T ForstP Stein
Apr 12, 2014·Current Opinion in Virology·Ragunath SingaraveluJohn Paul Pezacki
Apr 20, 2014·BMC Endocrine Disorders·Alan SinclairGary Meininger
Sep 11, 2014·Diabetes Care·Lawrence A LeiterGary Meininger
Oct 29, 2014·Journal of Medical Economics·Marie-Hélène LafeuillePatrick Lefebvre
Oct 31, 2014·Current Medical Research and Opinion·Erin K BuysmanMarcia F T Rupnow
Dec 17, 2014·Diabetes, Obesity & Metabolism·B BodeG Meininger
Dec 30, 2014·Diabetes Care
Dec 30, 2014·Diabetes Care·Silvio E InzucchiDavid R Matthews
Mar 18, 2015·Lancet·Thaminda LiyanageVlado Perkovic
Jun 30, 2015·Current Medical Research and Opinion·James R GavinGary Meininger
Apr 1, 2014·Clinical Diabetes : a Publication of the American Diabetes Association·Dawn M Battise
Sep 17, 2015·Current Medical Research and Opinion·Lawrence BlondeGary Meininger
Oct 10, 2015·Diabetes, Obesity & Metabolism·Greg FulcherUNKNOWN CANVAS trial collaborative group
Mar 5, 2016·Current Medical Research and Opinion·Sarah ThayerRichard Aguilar
Mar 10, 2016·Obstetrics and Gynecology·Silvio E Inzucchi, Sachin K Majumdar
Apr 27, 2016·Current Medical Research and Opinion·Patrick LefebvreMei Sheng Duh
Aug 20, 2016·Journal of the American Society of Nephrology : JASN·Hiddo J L HeerspinkVlado Perkovic
Sep 21, 2016·Current Medical Research and Opinion·June Felice JohnsonRobert Bailey
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
May 13, 2017·Clinical Therapeutics·June Felice JohnsonRobert A Bailey
Jun 10, 2017·BMC Endocrine Disorders·Carol H WyshamMei Sheng Duh
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group